Check out our latest Validated PK & ADA Methods List Read about Veeda's partnership with Ahammune Biosciences for first in human studies Watch our Latest Symposium on Immuno-centric Approach to Biosimilar and Vaccine Development Check out our Assay List (Method Library)

Providing Integrated Services for the development of Biosimilars

Characterization

  • Bioassay Solution
  • Functional Characterization

Pre-clinical

  • Bioanalytical Assays
  • Animal Studies

Clinical

  • Human Studies
  • Clinical Assays

Biosimilar Analytical Characterization

Biocomparability Testing Solutions

Wide range of Biocomparability testing solutions so that you can test your biosimilar early in the development process and minimize the risk of failure during late phases of the drug development.

Bioassay Solutions

Evaluate the functionality of your biosimilar using a cell-based assay based on the drug’s mechanism of action such as cell proliferation, cell viability, cell signalling, receptor activation, and ligand binding assays to measure various downstream proteins.

Antibody Functionality Testing

Evaluate antibody function utilizing the following assays: ADCC assays, CDC assays, Fc Receptor binding assays (i.e, FcγRI(CD64), FcγRII(CD32a), FcγRIII(CD16a), and FcRn etc.) and C1q binding assays.

Our Services

Pharmacokinetic (PK Testing)

  • PK assays for Biosimilars
  • Comparability of originator and biosimilar

Immunogenicity Testing

  • ELISA
  • Cell-Bases Nab
  • ELISpot

Biomarker Testing

  • Gene Expression
  • Protein Expression
  • Cellular Profiling
  • Cell-based Functional

Approximately 137 validated methods supporting 70 biosimilar/bio-better molecules

Innovative Technology Platforms

AegyrisTM

AegyrisTM is designed to enable bioanalytical scientists to perform method validation, statistical analysis, and validation workflow management in a streamlined and regulatory-compliant manner.

Cutting edge cloud-based Aegyris™ that can save up to 70% of time and costs in method validation support activities

AmplattoTM

Ultrasensitive Immuno-PCR platform

Combines traditional immunoPCR workflow with proprietary nanoparticle technology to enable the detection of the analyte with unparalleled sensitivity and accuracy.

Intelli.bTM

Biosimilar Characterization Solutions
  • Platform based on more than 1000 antibodies generated against various innovator drugs
  • The antibodies bind to innovator and biosimilar products in an ELISA based system to generate “meaningful finger-print-like analysis”
  • This fingerprint is supported by an intelligent library to generate meaningful and actionable interpretation.

Symposium on Immuno-centric Approach to Biosimilar and Vaccine Development

Request for Proposal

Submit your details and we’ll be in touch shortly. You can also email us if you would prefer.